Federal Register / Vol. 87, No. 67 / Thursday, April 7, 2022 / Notices 20417 

requirement, CMS is publishing this 

notice. 

Information Collection 

1. Type of Information Collection 

Request: Reinstatement without change 

of a previously approved collection; 

Title of Information Collection: 

Federally Qualified Health Center Cost 

Report Form; Use: The Form CMS–224– 

14 cost report is needed to determine a 

provider’s reasonable cost incurred in 

furnishing medical services to Medicare 

beneficiaries and to calculate the FQHC 

settlement amount. These providers, 

paid under the FQHC prospective 

payment system (PPS), may receive 

reimbursement outside of the PPS for 

Medicare reimbursable bad debts, 

pneumococcal, influenza, and COVID– 

19 vaccines, and monoclonal antibody 

products. CMS uses the Form CMS– 

224–14 for rate setting; payment 

refinement activities, including 

developing a FQHC market basket; 

Medicare Trust Fund projections; and to 

support program operations. 

Additionally, the Medicare Payment 

Advisory Commission (MedPAC) uses 

the FQHC Medicare cost report data to 

calculate Medicare margins; to 

formulate recommendations to Congress 

regarding the FQHC PPS; and to 

conduct additional analysis of the 

FQHC PPS. Form Number: CMS–224–14 

(OMB control number: 0938–1298); 

Frequency: Yearly; Affected Public: 

Private Sector, State, Local, or Tribal 

Governments, Federal Government, 

Business or other for-profits, Not-forProfit Institutions; Number of 

Respondents: 2,890; Total Annual 

Responses: 2,890; Total Annual Hours: 

167,620. (For policy questions regarding 

this collection contact LuAnn Piccione 

at 410–786–5423.) 

2. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Medicare Part C 

and Part D Data Validation (42 CFR 

422.516(g) and 423.514(j)); Use: Sections 

1857(e) and 1860D–12 of the Social 

Security Act (‘‘the Act’’) authorize CMS 

to establish information collection 

requirements with respect to MAOs and 

Part D sponsors. Section 1857(e)(1) of 

the Act requires MAOs to provide the 

Secretary of the Department of Health 

and Human Services (DHHS) with such 

information as the Secretary may find 

necessary and appropriate. Section 

1857(e)(1) of the Act applies to 

Prescription Drug Plans (PDPs) as 

indicated in section1860D–12. Pursuant 

to statutory authority, CMS codified 

these information collection 

requirements in regulation at 

§§ 422.516(g) Validation of Part C 

Reporting Requirements, and 423.514(j) 

Validation of Part D Reporting 

Requirements respectively. 

Data collected via Medicare Part C 

and Part D reporting requirements are 

an integral resource for oversight, 

monitoring, compliance and auditing 

activities necessary to ensure quality 

provision of Medicare benefits to 

beneficiaries. CMS uses the findings 

collected through the data validation 

process to substantiate the data reported 

via Medicare Part C and Part D reporting 

requirements. Data validation provides 

CMS with assurance that plan-reported 

data are credible and consistently 

collected and reported by Part C and D 

SOs. CMS uses validated data to 

respond to inquiries from Congress, 

oversight agencies, and the public about 

Part C and D SOs. The validated data 

also allows CMS to effectively monitor 

and compare the performance of SOs 

over time. Validated plan-reported data 

may be used for Star Ratings, Display 

measures and other performance 

measures. Additionally, SOs can take 

advantage of the DV process to 

effectively assess their own performance 

and make improvements to their 

internal operations and reporting 

processes. Form Number: CMS–10305 

(OMB control number: 0938–1115); 

Frequency: Yearly; Affected Public: 

State, Local, or Tribal Governments; 

Number of Respondents: 793; Total 

Annual Responses: 793; Total Annual 

Hours: 21,535. (For policy questions 

regarding this collection contact 

Chanelle Jones at 410–786–8008.) 

Dated: April 4, 2022. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2022–07426 Filed 4–6–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; ORR–1, 

Cash and Medical Assistance Program 

Estimates 

AGENCY: Office of Refugee Resettlement, 

Administration for Children and 

Families, HHS. 

ACTION: Request for public comment. 

SUMMARY: The Office of Refugee 

Resettlement (ORR), Administration for 

Children and Families (ACF), U.S. 

Department of Health and Human 

Services (HHS) is requesting a 3-year 

extension of the form ORR–1, Cash and 

Medical Assistance Program Estimates 

(OMB #0970–0030, expiration 5/21/ 

2022). There are no changes requested 

to the form or instructions. 

DATES: Comments due within 30 days of 

publication. OMB must make a decision 

about the collection of information 

between 30 and 60 days after 

publication of this document in the 

Federal Register. Therefore, a comment 

is best assured of having its full effect 

if OMB receives it within 30 days of 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. You can also obtain 

copies of the proposed collection of 

information by emailing infocollection@

acf.hhs.gov. Identify all emailed 

requests by the title of the information 

collection. 

SUPPLEMENTARY INFORMATION: 

Description: The ORR–1, Cash and 

Medical Assistance Program Estimates, 

is the application for grants under the 

Cash and Medical Assistance (CMA) 

program. The application is required by 

ORR program regulations at 45 CFR 

400.11(b). The regulation specifies that 

states must submit, as their application 

for this program, estimates of the 

projected costs they anticipate incurring 

in providing cash and medical 

assistance for eligible recipients and the 

costs of administering the program. 

Under the CMA program, states are 

reimbursed for the costs of providing 

these services and benefits for 8 months 

after an eligible recipient arrives in this 

country. The eligible recipients for these 

services and benefits are refugees, 

Amerasians, Cuban and Haitian 

Entrants, asylees, Afghans and Iraqi 

with Special Immigrant Visas, and 

victims of a severe form of trafficking. 

States that provide services for 

unaccompanied refugee minors also 

provide an estimate for the cost of these 

services for the year for which they are 

applying for grants. 

Respondents: State Agencies, the 

District of Columbia, and Replacement 

Designees under 45 CFR 400.301(c) 

administering or supervising the 

administration of programs under Title 

IV of the Act. 


khammond on DSKJM1Z7X2PROD with NOTICES
20418 Federal Register / Vol. 87, No. 67 / Thursday, April 7, 2022 / Notices 

ANNUAL BURDEN ESTIMATES

Instrument 

Total 

number of 

respondents 

Annual 

number of 

responses per 

respondent 

Average 

burden hours 

per response 

Annual 

burden hours 

ORR–1, Cash and Medical Assistance Program Estimates ........................... 57 1 0.6 34 

Estimated Total Annual Burden 

Hours: 34. 

Authority: 8 U.S.C. 412(a)(4). 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–07369 Filed 4–6–22; 8:45 am] 

BILLING CODE 4184–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2021–N–1302] 

Pediatric Oncology Subcommittee of 

the Oncologic Drugs Advisory 

Committee; Notice of Meeting; 

Establishment of a Public Docket; 

Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; establishment of a 

public docket; request for comments. 

SUMMARY: The Food and Drug 

Administration (FDA) announces a 

forthcoming public advisory committee 

meeting of the Pediatric Oncology 

Subcommittee of the Oncologic Drugs 

Advisory Committee. The general 

function of the subcommittee is to 

provide advice and recommendations to 

FDA on regulatory issues. The meeting 

will be open to the public. FDA is 

establishing a docket for public 

comment on this document. 

DATES: The meeting will be held on May 

11, 2022, from 10 a.m. to 3:30 p.m. and 

May 12, 2022, from 10 a.m. to 3:30 p.m. 

Eastern Time. 

ADDRESSES: Please note that due to the 

impact of this COVID–19 pandemic, all 

meeting participants will be joining this 

advisory committee meeting via an 

online teleconferencing platform. 

Answers to commonly asked questions 

about FDA advisory committee meetings 

may be accessed at: https://

www.fda.gov/AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm408555.htm. 

FDA is establishing a docket for 

public comment on this meeting. The 

docket number is FDA–2021–N–1302. 

The docket will close on May 10, 2022. 

Submit either electronic or written 

comments on this public meeting by 

May 10, 2022. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before May 10, 2022. 

The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of May 10, 2022. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Comments received on or before April 

27, 2022, will be provided to the 

subcommittee. Comments received after 

that date will be taken into 

consideration by FDA. In the event that 

the meeting is cancelled, FDA will 

continue to evaluate any relevant 

applications or information, and 

consider any comments submitted to the 

docket, as appropriate. 

You may submit comments as 

follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2021–N–1302 for ‘‘Pediatric Oncology 

Subcommittee of the Oncologic Drugs 

Advisory Committee; Notice of Meeting; 

Establishment of a Public Docket; 

Request for Comments.’’ Received 

comments, those filed in a timely 

manner (see ADDRESSES), will be placed 

in the docket and, except for those 

submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ FDA 

will review this copy, including the 

claimed confidential information, in its 

consideration of comments. The second 

copy, which will have the claimed 

confidential information redacted/ 

blacked out, will be available for public 

viewing and posted on https://

www.regulations.gov. Submit both 

copies to the Dockets Management Staff. 

If you do not wish your name and 

contact information be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify the information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 


khammond on DSKJM1Z7X2PROD with NOTICES